A randomized, placebo‐ and active‐controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Vieta E, Nuamah IF, Lim P, Yuen EC, Palumbo JM, Hough DW, Berwaerts J. A randomized, placebo‐ and active‐controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. Bipolar Disord 2010: 12: 230–243. © 2010 The Authors. Journal compilation © 2010 John Wiley & Sons A/S. Objectives: To evaluate the antimanic efficacy and safety of paliperidone extended‐release (ER) tablets in patients with bipolar I disorder. Methods: This study included a 3‐week, double‐blind, acute treatment phase (paliperidone ER versus placebo, with quetiapine as control), and a 9‐week, double‐blind, maintenance phase (paliperidone ER versus quetiapine). Patients [n = 493; Young Mania Rating Scale (YMRS) score ≥ 20] were randomized (2:2:1) to flexibly dosed paliperidone ER (3–12 mg/day), quetiapine (400–800 mg/day), or placebo for the acute treatment phase. During the maintenance phase, patients assigned to placebo were switched to paliperidone ER but not included in analysis of efficacy. Results: Paliperidone ER was superior to placebo at the 3‐week endpoint {primary outcome; least‐squares mean difference in change from baseline in YMRS scores [95% confidence interval (CI)]: −5.5 (−7.57; −3.35); p < 0.001} and noninferior to quetiapine at the 12‐week endpoint [least‐squares mean difference (95% CI): 1.7 (−0.47; 3.96)]. The median mode dose during the 12‐week treatment period was 9 mg for paliperidone ER and 600 mg for quetiapine. The most common (≥ 10%) treatment‐emergent adverse events during the 12‐week period were: headache (16%), somnolence (10%), and akathisia (10%) for paliperidone ER; somnolence (21%), sedation and dry mouth (17% each), headache (14%), and dizziness (13%) for quetiapine. Body weight increase ≥ 7% from baseline to 12‐week endpoint was 8% with paliperidone ER and 17% with quetiapine. A higher percentage of paliperidone ER (13.9%) versus quetiapine patients (7.5%) ‘switched to depression’ at the12‐week endpoint. Conclusions: Paliperidone ER (3–12 mg/day) was efficacious and tolerable in the treatment of acute mania.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)
American Psychiatric Association (2000) · doi:10.1176/appi.books.9780890423349 · Cited by 11,069
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744
Assessment of suicidal intention: The Scale for Suicide Ideation.
Beck, A. T., Kovacs, M., & Weissman, A. (1979) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.47.2.343 · Cited by 3,419
Treatment Adherence With Lithium and Anticonvulsant Medications Among Patients With Bipolar Disorder
Sajatovic, M., Valenstein, M., Blow, F., Ganoczy, D., & Ignacio, R. (2007) · Psychiatric Services · doi:10.1176/ps.2007.58.6.855 · Cited by 172 · cited 1×
“0 [3–7] 4.”
Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder
Fountoulakis, K. N., Vieta, E., Siamouli, M., Valenti, M., Magiria, S., Oral, T., Fresno, D., Giannakopoulos, P., & Kaprinis, G. S. (2007) · Annals of General Psychiatry · doi:10.1186/1744-859x-6-27 · Cited by 76
Self-citation
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,217
Wolff, A., Joshi, R. K., Ekström, J., Aframian, D., Pedersen, A. M. L., Proctor, G., Narayana, N., Villa, A., Sia, Y. W., Aliko, A., et al. (2017) · Drugs in R&D · doi:10.1007/s40268-016-0153-9 · Cited by 364
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Azorin, J.-M., Yatham, L., Mosolov, S., Möller, H.-J., Kasper, S., et al. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1384850 · Cited by 187
“Three weeks of ER-paliperidone was superior to placebo in manic symptom reductions, and was non-inferior to quetiapine at 9-weeks follow-up, an effect not due to the baseline diagnosis of mixed or manic episode (P¼ 0.3) (Vieta et al. 2010).”
BackgroundResultInfluentialSelf-citationBerwaerts, J., Melkote, R., Nuamah, I., & Lim, P. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.01.047 · Cited by 101
Self-citationTreatment of mixed bipolar states
Fountoulakis, K. N., Kontis, D., Gonda, X., Siamouli, M., & Yatham, L. N. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001817 · Cited by 68
“Paliperidone was not found to precipitate depression in mixed patients (Vieta et al. 2010).”
BackgroundResultInfluential
Metadata
- Authors
- Vieta, E., Nuamah, I. F., Lim, P., Yuen, E. C., Palumbo, J. M., Hough, D. W., & Berwaerts, J.
- Venue
- Bipolar Disorders
- Publisher
- Wiley
- Published
- 2010-05
- Volume
- 12
- Issue
- 3
- Pages
- 230-243
- ISSN
- 1398-5647 (ISSN-L)
- 1399-5618
- OpenAlex
- W1942315088
- Cited by
- 122
- References
- 5
- FWCI
- 8.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A randomized, placebo‐ and active‐controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. https://app.cochat.ai/papers/10.1111/j.1399-5618.2010.00815.x
- The paper
- Vieta, E., Nuamah, I. F., Lim, P., Yuen, E. C., Palumbo, J. M., Hough, D. W., & Berwaerts, J. (2010). A randomized, placebo‐ and active‐controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. Bipolar Disorders. https://doi.org/10.1111/j.1399-5618.2010.00815.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.